Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
15 Maio 2023 - 8:30AM
Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose
– Unleashing tools to accelerate breakthroughs in human health
– announced the appointment of Jeffrey Black as Senior Vice
President and Chief Financial Officer effective today. Black will
lead Standard BioTools’ finance, accounting and investor relations
functions, reporting to Michael Egholm, Ph.D., President and Chief
Executive Officer. Vikram Jog will remain at the company for a
period as Special Advisor to the CEO to ensure an effective
transition.
“We are excited to welcome Jeff to the Standard BioTools
executive leadership team. Jeff has a proven track record of
driving performance for high-growth public companies and his
extensive operating experience and financial stewardship will be
critical as Standard BioTools enters its next phase of growth,”
said Egholm. “I also want to extend my gratitude to Vikram, who has
been a steady hand and clear thinker as we navigated the strategic
transformation throughout our first year as Standard Biotools.”
Mr. Black was most recently Chief Financial Officer at Apollo
Endosurgery, Inc. until Apollo’s acquisition by Boston Scientific
in April 2023. Mr. Black has also served in senior finance
leadership roles for seven publicly traded companies, including as
Executive Vice President and Chief Financial Officer of Alphatec
Holdings, Inc., a medical technology company. Previously, Mr. Black
was Chief Financial Officer of Applied Proteomics, Inc., a
proteomics-based diagnostics company, and as Chief Financial
Officer of AltheaDx, Inc., a pharmacogenetics diagnostics company.
Mr. Black began his career in the audit practice at EY. He is a
member of the Board of Directors of Cellana, Inc., an algae
bioproducts company, and received his B.S. in Business from the
University of Arizona.
“I am thrilled to join this high-caliber leadership team and
dynamic organization,” said Black. “This team is building an
exceptional company that will be the next great provider of
solutions to researchers around the world. There is a tremendous
opportunity ahead to greatly impact patient lives and unlock
shareholder value. I am delighted to be a part of Standard BioTools
as it continues to execute on its mission.”
As a material inducement for Mr. Black to commence employment
with Standard BioTools, on May 15, 2023, Mr. Black will receive an
award of non-statutory stock options to purchase 400,000 shares of
the Company’s common stock (“Option Award”). The Option Award will
have a 10-year term and an exercise price per share equal to the
closing price of the company’s common stock as quoted on the Nasdaq
Global Select Market on May 15, 2023. Subject to his continued
employment with the company through the applicable vesting dates,
25% of the shares subject to the Option Award will vest on the
first anniversary of the vesting commencement date, and the
remaining 75% of the shares subject to the Option Award will vest
in roughly equal monthly installments thereafter. In addition, as a
material inducement for Mr. Black to commence employment with the
company, on May 15, 2023 he will receive an award of restricted
stock units valued at $400,000 (“RSU Award”) based on the closing
price of the company’s common stock on May 15, 2023. Subject to his
continued employment with the company, 25% of the shares underlying
the RSU Award will vest on the first anniversary of the vesting
commencement date and the remaining 75% of the shares underlying
the RSU Award will vest in roughly equal installments every three
months thereafter until fully vested in May 2027. The Option Award
and RSU Award will be subject to the terms of the company’s 2022
Inducement Equity Incentive Plan and the applicable award
agreements thereunder. In accordance with Nasdaq Listing Rule
5635(c)(4), a majority of the independent directors serving on the
company’s Board of Directors approved Mr. Black’s inducement
awards.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), previously known as
Fluidigm Corporation, is driven by a bold purpose – Unleashing
tools to accelerate breakthroughs in human health. Standard
BioTools has an established portfolio of essential, standardized
next-generation technologies that help biomedical researchers
develop medicines faster and better. As a leading solutions
provider, the company provides reliable and repeatable insights in
health and disease using its proprietary mass cytometry and
microfluidics technologies, which help transform scientific
discoveries into better patient outcomes. Standard BioTools works
with leading academic, government, pharmaceutical, biotechnology,
plant and animal research, and clinical laboratories worldwide,
focusing on the most pressing needs in translational and clinical
research, including oncology, immunology, and immunotherapy. Learn
more at www.standardbio.com or connect with us on Twitter®,
Facebook®, LinkedIn, and YouTube™. Standard BioTools, the Standard
BioTools logo, Fluidigm, the Fluidigm logo, “Unleashing tools to
accelerate breakthroughs in human health,” Hyperion, Hyperion XTi,
XTi, and X9 are trademarks and/or registered trademarks
of Standard BioTools Inc. or its affiliates in the
United States and/or other countries. All other trademarks are
the sole property of their respective owners. Standard
BioTools products are provided for Research Use
Only. Not for use in diagnostic procedures.
Available Information
Standard BioTools uses its website (standardbio.com),
investor site (investors.standardbio.com), corporate Twitter
account (@Standard_BioT), Facebook page
(facebook.com/StandardBioT), and LinkedIn page
(linkedin.com/company/standard-biotools) as channels of
distribution of information about its products, its planned
financial and other announcements, its attendance at upcoming
investor and industry conferences, and other matters. Such
information may be deemed material information, and Standard
BioTools may use these channels to comply with its disclosure
obligations under Regulation FD. Therefore, investors should
monitor Standard BioTools’ website and its social media accounts in
addition to following its press releases, SEC filings,
public conference calls, and webcasts.
Investor Contacts
Scott R. Greenstone, CFAir@standardbio.com
Peter DeNardo 415 389 6400 ir@standardbio.com
Standard BioTools (NASDAQ:LAB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Standard BioTools (NASDAQ:LAB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024